I'm with you tada, something's gotta give for financing the work ahead, and stabilizing this technology for the future.

We have a lot more data now, and some juicy potential markets that it appears we can address. Just need to understand the Cognition part better in early Dec.

Then wait and see what the FDA comes back with for us, for the path/time/costs ahead?

Anyway, and moreover, RVX will have mostly everything it needs by mid-December to have pretty direct and straight up discussion regarding advancement strategies ... with the added Cognition and FDA pieces adjusting ask/bid up or down, however they may?

As it sits now, a tremendous amount of work has been done that a BP would not have to replicate or pay the expense, with some sizable markets looking good for openers in the next 1-5 years depending on the path? ....

Break-through status in one or more areas would be huge for time/expense, and also a strong "confidence" factor with the FDA, for a potential suitor? ... I would think/hope the FDA letter information is considered material and is disclosed to the investors/public. 

Just some rambling thoughts, and jmho's